In mouse models, CLDN6-CAR1 NK cells effectively eradicated ovarian cancer cells from both subcutaneous and intra-abdominal sites, and when used in combination with the immune checkpoint inhibitor anti-PD-L1, they synergistically enhanced anti-tumor efficacy. This evidence concerns the gene CLDN6 and ovarian carcinoma.